UCSF is home to some of the world’s foremost experts in genomic immunology and cellular engineering. These partnerships and endeavors are developing an unprecedented understanding of the genetic programs governing human immune cell function and dysfunction, and transformative opportunities in immunotherapies.
The vision of the Living Therapeutics Initiative (LTI) is to harness the vast scientific talent and clinical expertise at UCSF. The mission is to advance future promising cellular therapies from early discovery through proof-of-concept studies and into clinical trial evaluation to provide meaningful therapeutic solutions and inform future innovations.
The Gladstone-UCSF Institute of Genomic Immunology blends the latest genomics and genome-engineering technologies with immunology research to engineer the human immune system for therapeutic benefit.
This program unites researchers at UCSF, Gladstone Institutes, and the Innovative Genomics Institute at UC Berkeley to accelerate the development of novel therapies for a wide variety of cancers by combining genetic discovery and design with innovations in CRISPR technology.
An innovative research program that promotes collaborative, cutting-edge research and data sharing to catalyze discoveries about the central role of the immune system in human health and harness its power to treat a wide range of diseases, including cancer.